ArticleJournal of bone oncology2015

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

Christina L Addison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.